Neuroscientific Biopharmaceuticals Ltd has released a press release.
EmtinB Can Become a Revolutionary Treatment for Glaucoma
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Earlier from Neuroscientific Biopharmaceuticals
- NSB Receives R&D Advanced Overseas Finding
- NSB - FInal Data Received from Spinal Cord Injury Model
- NSB - Breakthrough results from Spinal Cord Injury Model
- Appendix 4D & Half-Year Financial Statements
- Non-Renounceable Issue Prospectus
Later from Neuroscientific Biopharmaceuticals
- AGM Address
- NSB - Company Update
- CVN Model Indicates Neuroprotective Properties of EmtinB
- Additional US Patent granted
- Positive Results in Glaucoma Pig Model
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals